Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Kicks Can Down Road By Pushing MCIT Breakthrough Devices Rule To Dec. 15. Here’s Why

Executive Summary

In a move that will undoubtedly ruffle industry feathers, the US Medicare agency on 14 May issued a final rule that moves implementation of the Medicare Coverage of Innovative Technology rule to the end of the year.

You may also be interested in...



CMS Dashes Industry Hopes For MCIT Rule Any Time Soon

The US Medicare agency has proposed to withdraw a rule that would give temporary automatic coverage to breakthrough devices, stating the rule doesn’t meet its evidence threshold and could put patients at risk.­­­­­­­

ACA Champion Brooks-LaSure Confirmed As CMS Chief On 55-44 Senate Vote

Chiquita Brooks-LaSure, a key player in the passing and implementation of the Affordable Care Act, was confirmed on 25 May as the next administrator of the US Centers for Medicare and Medicaid Services. At least one industry group is already nudging her to put the Medicare Coverage of Innovative Technology (MCIT) rule for breakthrough devices into effect.

MCIT Rule Likely Too Broken For CMS To Implement In December, Analyst Predicts

John Leppard with Washington Analysis says the Medicare agency’s recent delay of the MCIT breakthrough devices rule until mid-December suggests the CMS will likely scrap it altogether and start from scratch.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143932

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel